Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2016

Krayem Mohammad, Journe Fabrice, Wiedig Murielle, Morandini Renato, Najem Ahmad, Salès François, van Kempen Leon C, Sibille Catherine, Awada Ahmad, Marine Jean-Christophe, Ghanem Ghanem

Abstract excerpt

Intrinsic and acquired resistance of metastatic melanoma to (V600E/K)BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway, represents a major clinical challenge. Given that p53 is capable of antagonising PI3K/AKT activation we hypothesised that pharmacological restoration of p53 activity may increase the sensitivity of BRAF-mutant melanoma to MAPK-targeted therapy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Phosphatidylinositol 3-Kinase

Share to Proto-Oncogene Proteins c-akt

Share to Sulfonamides

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 26790143
DOI: 10.1016/j.ejca.2015.12.002

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.PMID 26790143Read ↗

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Semantic proximity Read ↗

Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapySemantic proximity Read ↗

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.Semantic proximity Read ↗

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.Semantic proximity Read ↗

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Semantic proximity Read ↗

The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.Semantic proximity Read ↗

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in MelanomaSemantic proximity Read ↗

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Semantic proximity Read ↗

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.Semantic proximity Read ↗

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.Semantic proximity Read ↗

Inhibition of mutant <scp>BRAF</scp> splice variant signaling by next‐generation, selective <scp>RAF</scp> inhibitorsSemantic proximity Read ↗

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.